By Iain Gilbert
Date: Friday 10 Oct 2025
(Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.
By Josh White
Date: Thursday 29 May 2025
(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.
By Benjamin Chiou
Date: Tuesday 31 Dec 2024
(Sharecast News) - Autoimmune disease and cancer treatment developer Sareum has revealed that the commercial licence of its jointly developed SRA737 product has been terminated by a biopharma company in the US.
| Currency | UK Pounds |
| Share Price | 12.50p |
| Change Today | 0.25p |
| % Change | 2.04 % |
| 52 Week High | 28.00 |
| 52 Week Low | 11.25 |
| Volume | 154,413 |
| Shares Issued | 138.07m |
| Market Cap | £17.26m |
| RiskGrade | 594 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 17:05 | 8,990 @ 12.50p |
| 15:47 | 40,977 @ 12.18p |
| 14:15 | 2,019 @ 12.18p |
| 14:13 | 2,019 @ 12.18p |
| 13:24 | 10,000 @ 13.00p |
You are here: research